Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11212279
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL

  2000cited by this paper
• Molecular determinants of response to TRAIL in killing of normal and cancer cells.

  2000cited by this paper
• Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy.

  2000cited by this paper
• Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes.

  2000cited by this paper
• Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).

  2000cited by this paper
• Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.

  1999influential reference
• Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases

  1999cited by this paper
• Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11.

  1999cited by this paper
• Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.

  1999cited by this paper
• Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo

  1999cited by this paper
• An APAF-1·Cytochrome c Multimeric Complex Is a Functional Apoptosome That Activates Procaspase-9*

  1999cited by this paper
• Suicidal Tendencies: Apoptotic Cell Death by Caspase Family Proteinases*

  1999cited by this paper
• Chemotherapy in advanced prostate cancer.

  1999cited by this paper
• IAP family proteins--suppressors of apoptosis.

  1999cited by this paper
• Apoptosis control by death and decoy receptors.

  1999influential reference
• Apoptotic pathways: the roads to ruin.

  1998cited by this paper
• Control of apoptosis and mitotic spindle checkpoint by survivin

  1998cited by this paper
• Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

  1998cited by this paper
• TRAIL: a molecule with multiple receptors and control mechanisms.

  1998influential reference
• Apoptotic Pathways: The Roads to Ruin

  1998cited by this paper
• Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization.

  1998cited by this paper
• Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications

  1997cited by this paper
• FLAME-1, a Novel FADD-like Anti-apoptotic Molecule That Regulates Fas/TNFR1-induced Apoptosis*

  1997cited by this paper
• KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene

  1997cited by this paper
• Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells.

  1997influential reference
• Immortalized and tumorigenic adult human prostatic epithelial cell lines: Characteristics and applications part 2. Tumorigenic cell lines

  1997cited by this paper

• Remodeling tumor microenvironment using pH-sensitive biomimetic co-delivery of TRAIL/R848 liposomes against colorectal cancer

  2024cites this paper
• Investigating STEAP2 as a potential therapeutic target for the treatment of aggressive prostate cancer.

  2023cites this paper
• Recent Developments and Anticancer Therapeutics of Paclitaxel: An update.

  2022cites this paper
• Physodic acid sensitizes LNCaP prostate cancer cells to TRAIL-induced apoptosis.

  2022cites this paper
• Signaling Pathways That Control Apoptosis in Prostate Cancer

  2021cites this paper
• The effect of paclitaxel on apoptosis, autophagy and mitotic catastrophe in AGS cells

  2021cites this paper
• Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes

  2021cites this paper
• Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress

  2021cites this paper
• TRAIL therapy and prospective developments for cancer treatment.

  2020cites this paper
• Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib

  2020cites this paper
• Expression profiles of TRAIL and its receptors in normal, hyperplastic, and malignant endometrial tissues: Hints on endometrial cancer biology

  2019cites this paper
• Self-assembled peptide nanostructures targeting death receptor 5 and encapsulating paclitaxel as a multifunctional cancer therapy.

  2019cites this paper
• Combined strategies of tumor necrosis factor-related apoptosis-inducing ligand and small molecular drugs to inhibit pancreatic cancer cell proliferation and tumor growth

  2018cites this paper
• Immunohistochemical Analysis of the Extrinsic Apoptosis Process in the Non-Neoplastic and Neoplastic Prostate.

  2018cites this paper
• Boldine Activates Intrinsic Apoptotic Pathway in DU-145 Androgen-Independent Prostate Cancer Cell Line

  2018cites this paper
• Tubulin couples death receptor 5 to regulate apoptosis

  2018cites this paper
• Involvement of Bax and Bcl-2 in Induction of Apoptosis by Essential Oils of Three Lebanese Salvia Species in Human Prostate Cancer Cells

  2018cites this paper
• pluronic F 127 / P 123 silica nanocapsules with surface conjugated rhTRAIL for targeted cancer therapy

  2017cites this paper
• Sanguinarine-Mediated Sensitization of Cervical Cancer SiHa Cells to TRAIL

  2017cites this paper
• Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

  2017cites this paper
• Targeting Apoptotic Activity Against Prostate Cancer Stem Cells

  2017cites this paper
• TNF-related apoptosis-inducing ligand (TRAIL) for bone sarcoma treatment: Pre-clinical and clinical data.

  2017cites this paper
• Paclitaxel-loaded pluronic F127/P123 silica nanocapsules with surface conjugated rhTRAIL for targeted cancer therapy

  2017cites this paper
• Preparation, characterization and in vitro antitumor effect of cholesterol succinyl Bletilla striata polysaccharide-loaded paclitaxel nanoparticles

  2017cites this paper
• 3-Hydroxyterphenyllin, a natural fungal metabolite, induces apoptosis and S phase arrest in human ovarian carcinoma cells

  2017cites this paper
• The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL-induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells

  2016cites this paper
• Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies

  2016cites this paper
• Paclitaxel enhances tumoricidal potential of TRAIL via inhibition of MAPK in resistant gastric cancer cells.

  2016cites this paper
• Antiproliferative and Apoptotic Effect of Curcumin and TRAIL (TNF Related Apoptosis inducing Ligand) in Chronic Myeloid Leukaemic Cells.

  2016influential citation
• Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase*

  2015cites this paper
• miR‐130a activates apoptotic signaling through activation of caspase‐8 in taxane‐resistant prostate cancer cells

  2015cites this paper
• Overcoming Cancer Cell Resistance to Death Receptor Targeted Therapies

  2015cites this paper
• Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.

  2015cites this paper
• In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by Taxol

  2015cites this paper
• Phenethyl isothiocyanate upregulates death receptors 4 and 5 , sensitizes TRAIL-induced 1 apoptosis , and inhibits proliferation in human cancer stem-like cells

  2014cites this paper
• The long and winding road to cancer treatment: the TRAIL system.

  2014cites this paper
• Phenethyl isothiocyanate upregulates death receptors 4 and 5 and inhibits proliferation in human cancer stem-like cells

  2014cites this paper
• Prostate cancer: leading and misleading routes to TRAIL of death.

  2014cites this paper
• Gene Expression Profiling Associated with Angiotensin II Type 2 Receptor-Induced Apoptosis in Human Prostate Cancer Cells

  2014cites this paper
• Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs).

  2014cites this paper
• Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance

  2014influential citation
• Rab25 Small GTPase Mediates Secretion of Tumor Necrosis Factor Receptor Superfamily Member 11b (osteoprotegerin) Protecting Cancer Cells from Effects of TRAIL

  2013cites this paper
• Modulating cell-to-cell variability and sensitivity to death ligands by co-drugging

  2013cites this paper
• TRAIL-induced kinases activation and apoptosis: towards improved death receptor targeted therapy for lung cancer

  2013cites this paper
• Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy

  2013cites this paper
• Caspase-8 as a therapeutic target in cancer.

  2013cites this paper
• On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics

  2013cites this paper
• Human Cancer Resistance to Trail-Apoptotic Pathway-Targeted Therapies

  2013cites this paper
• Szlak liganda czynnika martwicy nowotworu indukującego apoptozę (TRAIL) jako potencjalny cel terapii w raku prostaty

  2013cites this paper
• AVALIAÇÃO DA MORTE CELULAR INDUZIDA PELA ASSOCIAÇÃO DE PACLITAXEL E CISPLATINA EM LINHAGENS CELULARES DERIVADAS DE TUMOR DE CABEÇA E PESCOÇO

  2013cites this paper
• TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology

  2013cites this paper
• Combination of Albendazole and 2-Methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice

  2013influential citation
• Upregulation of DR5 receptor by the diaminothiazole DAT1 [4-amino-5-benzoyl-2-(4-methoxy phenyl amino) thiazole] triggers an independent extrinsic pathway of apoptosis in colon cancer cells with compromised pro and antiapoptotic proteins

  2013cites this paper
• MicroRNAs: key players of taxane resistance and their therapeutic potential in human cancers

  2013cites this paper
• Resistance to TRAIL and how to surmount it

  2012cites this paper
• The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.

  2012cites this paper
• Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels

  2012cites this paper
• The Molecular Mechanisms of 5-Fluorouracil-Induced Apoptosis in Human Colorectal Cancer Cells and the Use of 5-FU as a Sensitising Agent to TRAIL

  2012cites this paper
• A new jasmonic acid stereoisomeric derivative induces apoptosis via reactive oxygen species in human prostate cancer cells.

  2012cites this paper
• Effect of vicanicin and protolichesterinic acid on human prostate cancer cells: role of Hsp70 protein.

  2012cites this paper
• Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand.

  2012cites this paper
• NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: implications for tumor growth retardation and docetaxel sensitivity.

  2012cites this paper
• TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.

  2012cites this paper
• Ethanol promotes cytotoxic effects of tumor necrosis factor-related apoptosis-inducing ligand through induction of reactive oxygen species in prostate cancer cells

  2012cites this paper
• Efficacy and Mechanistic Evaluation of Tic10, A Novel Antitumor Agent

  2012cites this paper
• Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types.

  2012cites this paper
• PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy.

  2011cites this paper
• Targeting TRAIL towards the clinic.

  2011cites this paper
• Synergistic anticancer effects achieved by co-delivery of TRAIL and paclitaxel using cationic polymeric micelles.

  2011cites this paper
• Advances in Viral Vector-Based TRAIL Gene Therapy for Cancer

  2011cites this paper
• Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

  2011cites this paper
• Identification of novel therapeutic targets in mastocytosis:Inhibition of survival of neoplastic mast cells by targeting IAPs and TRAIL receptors

  2011cites this paper
• Sensitization of glioma to death receptor 5-mediated apoptosis through genotoxic stress and cell cycle disruption: A study of mechanism

  2011cites this paper
• High Cell Surface Death Receptor Expression Determines Type I Versus Type II Signaling*

  2011cites this paper
• INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

  2010cites this paper
• Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis

  2010cites this paper
• Pro-apoptotic activity of ergosterol peroxide and (22E)-ergosta-7,22-dien-5alpha-hydroxy-3,6-dione in human prostate cancer cells.

  2010cites this paper
• Death receptors: targets for cancer therapy.

  2010cites this paper
• Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents

  2010cites this paper
• TRAILing death in cancer.

  2010cites this paper
• Current Endeavors for Enhancing Efficacy of Paclitaxel for Treatment of Glioblastoma

  2010cites this paper
• Molecular Mechanisms of Taxol for Induction of Cell Death in Glioblastomas

  2010cites this paper
• Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy.

  2010cites this paper
• Molecular Mechanisms of Taxol Induced Cell Death in Glioblastomas

  2009cites this paper
• TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.

  2009cites this paper
• Causes and consequences of genomic instability in prostatic carcinogenesis.

  2009cites this paper
• Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis.

  2009cites this paper
• Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2

  2009cites this paper
• Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells

  2009cites this paper
• Paclitaxel promotes a caspase 8-mediated apoptosis via death effector domain association with microtubules

  2009cites this paper
• TRAIL receptor signalling and modulation: Are we on the right TRAIL?

  2009cites this paper
• Targeting of TRAIL Apoptotic Pathways for Glioblastoma Therapies

  2009cites this paper
• TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.

  2009cites this paper
• To kill a tumor cell: the potential of proapoptotic receptor agonists.

  2008cites this paper
• Combined modality immunotherapy and chemotherapy: a new perspective

  2008cites this paper
• Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

  2008cites this paper
• Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel.

  2008cites this paper
• Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer.

  2008cites this paper
• Etude du ligand TRAIL et ses récepteurs dans la prostate normale et pathologique reliée au statut hormonal

  2008influential citation
• Prostatic preneoplasia and beyond.

  2008cites this paper